Post date August 11, 2021 Experience Adagio Therapeutics $356 million IPO We advised the underwriters on the IPO and Nasdaq listing
Post date July 26, 2021 Experience Natera $584.8 million follow-on offering We advised the underwriters on the SEC-registered stock offering
Post date April 29, 2021 Experience Digital Turbine $400 million revolving credit facility We advised the agent, lead arrangers and bookrunners on the facility
Post date April 29, 2021 Experience EDAP TMS $28 million follow-on offering We advised the underwriters on the equity offering
Post date April 1, 2021 Experience Beam Therapeutics $300 million at-the-market offering We advised the sales agent in connection with the equity offering
Post date March 30, 2021 Experience LAVA Therapeutics $100.5 million IPO We advised the underwriters on the IPO and Nasdaq listing
Post date March 16, 2021 Experience Prometheus Biosciences $218.5 million IPO We advised the underwriters on the IPO and Nasdaq listing
Post date March 2, 2021 Experience InflaRx $75 million follow-on offering We advised the underwriters on the equity offering
Post date February 17, 2021 Experience Charles River Laboratories $875 million acquisition of Cognate We advised Charles River on the acquisition of a cell and gene therapy contract development and manufacturing organization
Post date February 9, 2021 Experience Bolt Biotherapeutics $230 million IPO We advised the underwriters on the IPO and Nasdaq listing